Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

BACKGROUND: The IONESCO (IFCT-1601) trial assessed the feasibility of neoadjuvant durvalumab, for early-stage resectable non-small-cell lung cancer (NSCLC). METHODS: In a multicenter, single-arm, phase II trial, patients with IB (≥4 cm)-IIIA, non-N2, resectable NSCLC received three doses of durvalum...

Descripción completa

Detalles Bibliográficos
Autores principales: Wislez, Marie, Mazieres, Julien, Lavole, Armelle, Zalcman, Gérard, Carre, Olivier, Egenod, Thomas, Caliandro, Raffaele, Dubos-Arvis, Catherine, Jeannin, Gaelle, Molinier, Olivier, Massiani, Marie-Ange, Langlais, Alexandra, Morin, Franck, Le Pimpec Barthes, Francoise, Brouchet, Laurent, Assouad, Jalal, Milleron, Bernard, Damotte, Diane, Antoine, Martine, Westeel, Virginie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594538/
https://www.ncbi.nlm.nih.gov/pubmed/36270733
http://dx.doi.org/10.1136/jitc-2022-005636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594538/
https://www.ncbi.nlm.nih.gov/pubmed/36270733
http://dx.doi.org/10.1136/jitc-2022-005636

Ejemplares similares